Product Code: ETC6190897 | Publication Date: Sep 2024 | Updated Date: May 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The short bowel syndrome (SBS) drugs market in Australia is focused on providing treatments for individuals with SBS, a condition characterized by the malabsorption of nutrients due to the partial removal of the small intestine. Patients with SBS often experience complications such as diarrhea, dehydration, and malnutrition, making the development of effective drugs crucial. The market is driven by the increasing recognition of SBS as a significant healthcare issue, along with advances in drug development for managing the symptoms and improving the quality of life for patients. Current treatments primarily focus on intravenous nutrition, but newer drug therapies and medical devices are being developed to address the underlying causes of SBS and help restore normal digestive function.
The short bowel syndrome (SBS) drugs market in Australia is growing due to an increasing awareness of the condition and the development of novel therapeutic options. SBS, a disorder that occurs when a significant portion of the small intestine is removed, leads to nutritional deficiencies and requires long-term management. Pharmaceutical companies are focusing on developing treatments that address the malabsorption of nutrients, with innovations such as growth hormone therapies, GLP-2 analogs, and specialized nutritional products. There is also a rising demand for personalized treatment regimens that are tailored to the individual needs of patients. The Australian healthcare systems growing emphasis on advanced medical therapies, along with government initiatives to support innovative treatments for rare and complex diseases, is driving the market for SBS drugs.
The market for short bowel syndrome drugs in Australia faces challenges due to the relatively small patient population, which limits the market size and, consequently, the investment in research and development for new treatments. The high cost of these treatments, including specialized therapies such as parenteral nutrition, creates barriers to access for many patients. Additionally, the complexity of treatment regimens and the lack of widespread awareness of the condition among both the public and healthcare providers further complicate market growth. Regulatory hurdles, including approval processes for new drugs and therapies, also slow down the availability of innovative treatment options.
This rare condition presents a specialized but high-margin pharmaceutical opportunity. Investment potential lies in R&D collaboration with biotech firms, market entry of approved biologics, and hospital-based distribution networks across urban Australia.
The pharmaceutical market for Short Bowel Syndrome (SBS) drugs is tightly regulated by the Therapeutic Goods Administration (TGA). Government reimbursement policies under the Pharmaceutical Benefits Scheme (PBS) affect the accessibility and pricing of rare disease treatments. There is also growing public investment in orphan drugs through grants and partnerships with biotech firms, aligning with Australias National Strategic Action Plan for Rare Diseases.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Short Bowel Syndrome Drugs Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Short Bowel Syndrome Drugs Market - Industry Life Cycle |
3.4 Australia Short Bowel Syndrome Drugs Market - Porter's Five Forces |
3.5 Australia Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Australia Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Australia Short Bowel Syndrome Drugs Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Australia Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Short Bowel Syndrome Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Short Bowel Syndrome Drugs Market Trends |
6 Australia Short Bowel Syndrome Drugs Market, By Types |
6.1 Australia Short Bowel Syndrome Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Glucagon-like Peptide, 2021- 2031F |
6.1.4 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Anti-Diarrheal, 2021- 2031F |
6.1.5 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Histamine Blockers, 2021- 2031F |
6.1.6 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Proton Pump Inhibitors, 2021- 2031F |
6.1.7 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Growth Hormone, 2021- 2031F |
6.1.8 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Short Bowel Syndrome Drugs Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Short Bowel Syndrome Drugs Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Short Bowel Syndrome Drugs Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 Australia Short Bowel Syndrome Drugs Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Australia Short Bowel Syndrome Drugs Market Import-Export Trade Statistics |
7.1 Australia Short Bowel Syndrome Drugs Market Export to Major Countries |
7.2 Australia Short Bowel Syndrome Drugs Market Imports from Major Countries |
8 Australia Short Bowel Syndrome Drugs Market Key Performance Indicators |
9 Australia Short Bowel Syndrome Drugs Market - Opportunity Assessment |
9.1 Australia Short Bowel Syndrome Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Australia Short Bowel Syndrome Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Australia Short Bowel Syndrome Drugs Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Australia Short Bowel Syndrome Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Short Bowel Syndrome Drugs Market - Competitive Landscape |
10.1 Australia Short Bowel Syndrome Drugs Market Revenue Share, By Companies, 2024 |
10.2 Australia Short Bowel Syndrome Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |